NASDAQ:DVAXDynavax Technologies Stock Price, Forecast & News

Dynavax Technologies' stock was trading at $3.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DVAX stock has increased by 133.9% and is now trading at $7.18. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Dynavax Technologies.

Dynavax Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Dynavax Technologies.

Dynavax Technologies Co. (NASDAQ:DVAX) issued its quarterly earnings results on Wednesday, March, 11th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by $0.11. The biopharmaceutical company had revenue of $10.57 million for the quarter, compared to the consensus estimate of $11.92 million. Dynavax Technologies had a negative return on equity of 722.75% and a negative net margin of 310.97%. View Dynavax Technologies' earnings history.

4 Wall Street analysts have issued 12 month price objectives for Dynavax Technologies' shares. Their forecasts range from $12.00 to $20.00. On average, they anticipate Dynavax Technologies' share price to reach $16.00 in the next twelve months. This suggests a possible upside of 122.8% from the stock's current price. View analysts' price targets for Dynavax Technologies.

Media stories about DVAX stock have trended extremely negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Dynavax Technologies earned a media sentiment score of -4.6 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutDynavax Technologies.

Some companies that are related to Dynavax Technologies include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Medivation (MDVN), Incyte (INCY), First Solar (FSLR), United Continental (UAL), Micron Technology (MU), Array Biopharma (ARRY), Gilead Sciences (GILD) and Exelixis (EXEL).

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Dynavax Technologies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Federated Hermes Inc. (10.59%), BlackRock Inc. (6.81%), Chicago Capital LLC (4.81%), State Street Corp (3.71%), Blair William & Co. IL (2.17%) and Geode Capital Management LLC (1.32%). Company insiders that own Dynavax Technologies stock include Andrew A F Hack, David Louis Johnson, Francis Cano, Michael S Ostrach, Robert Coffman and Robert Janssen. View institutional ownership trends for Dynavax Technologies.

DVAX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Rhenman & Partners Asset Management AB, Rafferty Asset Management LLC, UBS Group AG, State Street Corp, Bank of New York Mellon Corp, Parametric Portfolio Associates LLC, and Weiss Multi Strategy Advisers LLC. Company insiders that have sold Dynavax Technologies company stock in the last year include Robert Coffman, and Robert Janssen. View insider buying and selling activity for Dynavax Technologies.

DVAX stock was bought by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Federated Hermes Inc., Blair William & Co. IL, Chicago Capital LLC, Squarepoint Ops LLC, Morgan Stanley, Thrivent Financial for Lutherans, and Geode Capital Management LLC. Company insiders that have bought Dynavax Technologies stock in the last two years include Andrew A F Hack, and Francis Cano. View insider buying and selling activity for Dynavax Technologies.

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DVAX stock can currently be purchased for approximately $7.18.

Dynavax Technologies has a market capitalization of $661.85 million and generates $35.22 million in revenue each year. The biopharmaceutical company earns $-152,600,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. Dynavax Technologies employs 231 workers across the globe.

The official website for Dynavax Technologies is www.dynavax.com.

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]